FDA RECALLS & COURT ACTIONS: May 26, 1993
Executive Summary
CLASS II UPDATE - Diazepam Injection, USP 5 mg/ml, and Cyanocobalamin Injection, 1,000 mcg/ml, Recall number: D-208/209-3, Manufacturer: Steris Laboratories, which appeared in the April 14, 1993 "Enforcement Report" ("The Pink Sheet" April 19, T&G-14) involves products distributed under the H. L. Moore label only. CLASS III - BULK GUAIFENENSIN USP In 50 or 50.6 kg fiber drums. Recall number: D-268-3. Lot numbers range between 22766 and 30921. Manufacturer: B.I. Chemical Corporation, Petersburg, Virginia. Recalled by: Manufacturer, by letter April 16 and 26, 1993. Firm-initiated recall ongoing. Distribution: Midwest and east coast; 157,063 kg were distributed Reason: Presence of aluminum particles.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth